

(English Translation of Consolidated Financial Statements and Report Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Consolidated Financial Statements

**With Independent Auditors' Review Report
For the Nine Months Ended September 30, 2025 and 2024**

Address: 5F.-6, No.23, Sec.1. Chang-An E. Rd., Taipei City 104, Taiwan (R.O.C.)
Telephone: +886-2-2571-0269

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Consolidated Balance Sheets	4
5. Consolidated Statements of Comprehensive Income	5
6. Consolidated Statements of Changes in Equity	6
7. Consolidated Statements of Cash Flows	7
8. Notes to the Consolidated Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the consolidated financial statements	8
(3) New standards, amendments and interpretations adopted	8~10
(4) Summary of material accounting policies	10~11
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	11
(6) Explanation of significant accounts	11~30
(7) Related-party transactions	30~31
(8) Assets Pledged as security	31
(9) Commitments and contingencies	31
(10) Losses Due to Major Disasters	31
(11) Subsequent Events	31
(12) Other	32
(13) Other disclosures	
(a) Information on significant transactions	33~34
(b) Information on investees	35
(c) Information on investment in mainland China	35
(14) Segment information	35~36



安侯建業聯合會計師事務所
KPMG

台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電 話 Tel + 886 2 8101 6666
傳 真 Fax + 886 2 8101 6667
網 址 Web kpmg.com/tw

3

Independent Auditors' Review Report

To the Board of Directors of Bioteque Corporation:

Introduction

We have reviewed the accompanying consolidated balance sheets of Bioteque Corporation (the “Company”) and its subsidiaries (together referred to as the “Group”) as of September 30, 2025 and 2024, and the related consolidated statements of comprehensive income for the three months and nine months ended September 30, 2025 and 2024, as well as the changes in equity and cash flows for the nine months ended September 30, 2025 and 2024, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, “Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Bioteque Corporation and its subsidiaries as of September 30, 2025 and 2024, and of its consolidated financial performance for the three months and nine months ended September 30, 2025 and 2024, as well as its consolidated cash flows for the nine months ended September 30, 2025 and 2024 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors' review report are Cheng, Po-Jen and Huang, Ming-Hung.

KPMG

Taipei, Taiwan (Republic of China)
November 6, 2025

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

September 30, 2025, December 31, 2024 and September 30, 2024

(Expressed in Thousands of New Taiwan Dollars)

	Assets				Liabilities and Equity				September 30, 2025				December 31, 2024				September 30, 2024				
	September 30, 2025		December 31, 2024		September 30, 2024				September 30, 2025		December 31, 2024		September 30, 2024								
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%	
Assets																					
Current assets :																					
1100 Cash and cash equivalents (note 6(a))	\$ 1,000,476	22	1,236,955	27	1,319,102	29	2130														
1110 Current financial assets at fair value through profit or loss (note 6(b))	121,632	3	120,280	3	119,834	3	2150														
1136 Current financial assets at amortized cost (note 6(c))	394,691	9	239,213	5	5,647	-	2170														
1150 Notes receivable, net (notes 6(d) and (n))	86,978	2	75,470	2	85,265	2	2209														
1170 Accounts receivable, net (notes 6(d) and (n))	194,211	4	192,657	4	192,593	4	2213														
130X Inventories (note 6(e))	299,601	7	320,701	7	287,323	7	2230														
1476 Other current financial assets (note 8)	601	-	601	-	601	-	2280														
1479 Other current assets	52,260	1	29,891	-	41,610	1	2322														
Total current assets	2,150,450	48	2,215,768	48	2,051,975	46	2399														
Non-current assets:																					
1600 Property, plant and equipment (notes 6(f) and 9)	1,947,569	43	2,030,526	44	2,034,936	45	2541														
1755 Right-of-use assets (note 6(g))	345,892	8	340,467	7	342,366	8	2570														
1840 Deferred tax asset	3,691	-	3,691	-	6,520	-	2580														
1915 Prepayments for business facilities (note 9)	33,964	1	45,325	1	46,665	1	2640														
1980 Other non-current financial assets	4,079	-	3,655	-	3,629	-															
1995 Other non-current assets	6,251	-	5,979	-	6,068	-															
Total non-current assets	2,341,446	52	2,429,643	52	2,440,184	54															
Total assets	\$ 4,491,896	100	4,645,411	100	4,492,159	100															
Liabilities and Equity																					
Current liabilities:																					
2130 Current contract liabilities (note 6(n))	\$ 63,316	2					2150														
2150 Notes payable	235	-					2170														
2170 Accounts payable	101,533	2					2209														
2209 Other payables (notes 6(j) and (o))	138,142	3					2213														
2213 Payable on machinery and equipment	8,166	-					2230														
2230 Current tax liabilities	39,099	1					2280														
2280 Current lease liabilities (note 6(i))	14,751	1					2322														
2322 Long-term borrowings, current portion (note 6(h))	147,025	3					2399														
2399 Other current liabilities	10,535	-																			
Total current liabilities	522,802	12																			
Non-Current liabilities:																					
2541 Long-term borrowings (note 6(h))	186,854	4					2570														
2570 Deferred tax liabilities	49,035	1					2580														
2580 Non-current lease liabilities (note 6(i))	289,711	7					2640														
2640 Net defined benefit liability, non-current	8,117	-																			
Total non-current liabilities	533,717	12																			
Total liabilities	1,056,519	24																			
Equity attributable to owners of parent (note 6(l)):																					
3100 Ordinary shares	692,983	15					3200														
3200 Capital surplus	317,029	7					3310														
3310 Retained earnings:							3350														
3350 Legal reserve	609,767	14					3350														
3350 Unappropriated retained earnings	1,813,611	40																			
	2,423,378	54																			
Other equity:																					
3410 Exchange differences on translation of foreign financial statements	1,987	-																			
	44,718	1																			
Total equity	3,435,377	76																			
Total liabilities and equity	\$ 4,491,896	1																			

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES**Consolidated Statements of Comprehensive Income****For the three months and nine months ended September 30, 2025 and 2024****(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Share)**

	For the three months ended September 30				For the nine months ended September 30				
	2025		2024		2025		2024		
	Amount	%	Amount	%	Amount	%	Amount	%	
4000	Operating revenue (note 6(n))	\$ 519,263	100	553,313	100	1,568,283	100	1,568,328	100
5000	Operating costs (notes 6(e), (f), (g), (j) and 12)	284,193	55	302,299	55	884,565	56	894,321	57
	Gross profit from operations	235,070	45	251,014	45	683,718	44	674,007	43
6000	Operating expenses (notes 6(f), (g), (i), (j), (o), 7 and 12):								
6100	Selling expenses	20,014	4	19,729	3	60,088	4	60,269	4
6200	Administrative expenses	29,416	6	26,528	5	79,601	5	76,648	5
6300	Research and development expenses	17,223	3	16,658	3	54,085	4	56,933	4
	Total operating expenses	66,653	13	62,915	11	193,774	13	193,850	13
6900	Net operating income	168,417	32	188,099	34	489,944	31	480,157	30
7000	Non-operating income and expenses (notes 6(i) and (p)):								
7100	Interest income	3,380	1	2,907	1	11,750	1	9,858	1
7010	Other income	882	-	6,350	1	3,853	-	8,780	1
7020	Other gains and losses	5,978	1	(10,445)	(2)	(18,046)	(1)	10,090	1
7050	Finance costs	(1,922)	-	(2,226)	(1)	(5,807)	-	(7,240)	(1)
	Total non-operating income and expenses	8,318	2	(3,414)	(1)	(8,250)	-	21,488	2
7900	Profit before tax	176,735	34	184,685	33	481,694	31	501,645	32
7951	Less: Tax expenses (note 6(k))	40,103	8	40,860	7	98,061	6	107,612	7
	Profit	136,632	26	143,825	26	383,633	25	394,033	25
8300	Other comprehensive income (loss) (note 6(l)):								
8360	Components of other comprehensive income (loss) that will be reclassified to profit or loss:								
8361	Exchange differences on translation	8,673	2	(10,795)	(2)	(42,731)	(3)	16,102	1
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	Total components of other comprehensive income (loss) that will be reclassified to profit or loss	8,673	2	(10,795)	(2)	(42,731)	(3)	16,102	1
8300	Other comprehensive income (loss), net	8,673	2	(10,795)	(2)	(42,731)	(3)	16,102	1
	Comprehensive income	\$ 145,305	28	\$ 133,030	24	\$ 340,902	22	\$ 410,135	26
9750	Basic earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)	\$ 1.97		\$ 2.08		\$ 5.54		\$ 5.69	
9850	Diluted earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)	\$ 1.97		\$ 2.07		\$ 5.51		\$ 5.66	

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES**Consolidated Statements of Changes in Equity****For the nine months ended September 30, 2025 and 2024**

(Expressed in Thousands of New Taiwan Dollars)

Balance at January 1, 2024

Net income for the nine months ended September 30, 2024

Other comprehensive income for the nine months ended September 30, 2024

Total comprehensive income for the nine months ended September 30, 2024

Appropriation and distribution of retained earnings:

Legal reserve

Special reserve

Cash dividends

Change in capital surplus

Balance at September 30, 2024**Balance at January 1, 2025**

Net income for the nine months ended September 30, 2025

Other comprehensive income for the nine months ended September 30, 2025

Total comprehensive income for the nine months ended September 30, 2025

Appropriation and distribution of retained earnings:

Legal reserve

Cash dividends

Change in capital surplus

Balance at September 30, 2025

	Attributable to owners of parent						Other equity	Exchange differences on translation of foreign financial statements	Total equity
				Retained earnings		Unappropriated retained earnings			
	Ordinary shares	Capital surplus	Legal reserve	Special reserve					
Balance at January 1, 2024	\$ 692,983	316,950	511,268	1,102	1,657,141		10,683		3,190,127
Net income for the nine months ended September 30, 2024	-	-	-	-	394,033		-		394,033
Other comprehensive income for the nine months ended September 30, 2024	-	-	-	-	-		16,102		16,102
Total comprehensive income for the nine months ended September 30, 2024	-	-	-	-	394,033		16,102		410,135
Appropriation and distribution of retained earnings:									
Legal reserve	-	-	45,642	-	(45,642)		-		-
Special reserve	-	-	-	(1,102)	1,102		-		-
Cash dividends	-	-	-	-	(311,843)		-		(311,843)
Change in capital surplus	-	(22)	-	-	-		-		(22)
Balance at September 30, 2024	\$ 692,983	316,928	556,910	-	1,694,791		26,785		3,288,397
Balance at January 1, 2025	\$ 692,983	317,032	556,910	-	1,829,327		44,718		3,440,970
Net income for the nine months ended September 30, 2025	-	-	-	-	383,633		-		383,633
Other comprehensive income for the nine months ended September 30, 2025	-	-	-	-	-		(42,731)		(42,731)
Total comprehensive income for the nine months ended September 30, 2025	-	-	-	-	383,633		(42,731)		340,902
Appropriation and distribution of retained earnings:									
Legal reserve	-	-	52,857	-	(52,857)		-		-
Cash dividends	-	-	-	-	(346,492)		-		(346,492)
Change in capital surplus	-	(3)	-	-	-		-		(3)
Balance at September 30, 2025	\$ 692,983	317,029	609,767	-	1,813,611		1,987		3,435,377

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES**Consolidated Statements of Cash Flows****For the nine months ended September 30, 2025 and 2024****(Expressed in Thousands of New Taiwan Dollars)**

	For the nine months ended September 30	
	2025	2024
Cash flows generated from (used in) operating activities:		
Profit before tax	\$ 481,694	501,645
Adjustments:		
Adjustments to reconcile profit (loss):		
Depreciation expenses	124,839	118,279
Amortization expenses	3,182	2,644
Net gains on financial assets at fair value through profit or loss	(1,352)	(1,243)
Interest expenses	5,807	7,240
Net gain (loss) on financial assets at amortized cost	3,585	(3,748)
Interest income	(11,750)	(9,858)
Losses on disposal of property, plant and equipment	-	5,943
Total adjustments to reconcile profit	<u>124,311</u>	<u>119,257</u>
Changes in operating assets:		
Notes receivable	(11,508)	(17,786)
Accounts receivable	(1,554)	(915)
Inventories	21,100	7,318
Other current assets	(21,052)	(7,478)
Total changes in operating assets	<u>(13,014)</u>	<u>(18,861)</u>
Changes in operating liabilities:		
Current contract liabilities	5,774	4,009
Notes payable	(54)	(21)
Accounts payable	(13,014)	(24,032)
Other payables	(2,129)	(3,457)
Other current liabilities	3,294	4,968
Net defined benefit liability	(60)	1
Total changes in operating liabilities	<u>(6,189)</u>	<u>(18,532)</u>
Total changes in operating assets and liabilities	<u>(19,203)</u>	<u>(37,393)</u>
Total adjustments	<u>105,108</u>	<u>81,864</u>
Cash inflow generated from operations	586,802	583,509
Interest received	9,407	8,626
Income taxes paid	(137,610)	(122,686)
Net cash flows generated from operating activities	<u>458,599</u>	<u>469,449</u>
Cash flows generated from (used in) investing activities:		
Acquisition of financial assets at amortized cost	(1,028,075)	(260,777)
Proceeds from disposal of financial assets at amortized cost	869,012	353,090
Acquisition of property, plant and equipment	(25,168)	(91,647)
Acquisition of right-of-use assets	(296)	(299)
Decrease (increase) in other financial assets	(424)	110
Increase in other non-current assets	(3,454)	(3,721)
Decrease (increase) in prepayments for business facilities	(19,300)	16,864
Increase (decrease) in payables on machinery and equipment	171	(79,460)
Net cash used in investing activities	<u>(207,534)</u>	<u>(65,840)</u>
Cash flows generated from (used in) financing activities:		
Repayments of long-term borrowings	(112,350)	(110,954)
Payment of lease liabilities	(10,605)	(9,593)
Cash dividend paid	(346,492)	(311,843)
Interest paid	(5,870)	(7,385)
Other financing activities	(3)	(22)
Net cash used in financing activities	<u>(475,320)</u>	<u>(439,797)</u>
Effect on exchange rate changes on cash and cash equivalents	<u>(12,224)</u>	<u>1,475</u>
Net increase in cash and cash equivalents	<u>(236,479)</u>	<u>(34,713)</u>
Cash and cash equivalents at beginning of period	<u>1,236,955</u>	<u>1,353,815</u>
Cash and cash equivalents at end of period	<u>\$ 1,000,476</u>	<u>1,319,102</u>

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

September 30, 2025 and 2024

**(Expressed in Thousands of New Taiwan Dollars Except for Earnings Per Share
Information and Unless Otherwise Specified)**

(1) Company history

Bioteque Corporation (“the Company”) was incorporated in November, 1991 in accordance with the Company Act and the other related laws and regulations.

The Company's stock was listed on Taipei Exchange on March 4, 2002.

The business operation of the Company and its subsidiaries (together referred to as “the Group”) are manufacturing, trading and selling of the medical consumables.

(2) Approval date and procedures of the consolidated financial statements:

The consolidated financial statements were authorized for issuance by the board of directors on November 6, 2025

(3) New standards, amendments and interpretations adopted:

(a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2025:

- Amendments to IAS21 “Lack of Exchangeability”
- (b) The impact of IFRS Accounting Standards endorsed by the FSC but not yet effective

The Group assesses that the adoption of the following new amendments, effective for annual period beginning on January 1, 2026, would not have a significant impact on its consolidated financial statements:

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards—Volume 11
- Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(c) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations	Content of amendment	Effective date per IASB
IFRS 18 "Presentation and Disclosure in Financial Statements"	<p>The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.</p> <ul style="list-style-type: none"> ● A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined 'operating profit' subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company's main business activities. ● Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards. ● Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes. 	<p>January 1, 2027 note:On September 25, 2025, the FSC issued a press release announcing that Taiwan will adopt IFRS 18 beginning in 2028. Entities that need to adopt the new standard earlier may do with the endorsement of the FSC.</p>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The Group is evaluating the impact on its consolidated financial position and consolidated financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures” and amendments to IFRS 19 “Subsidiaries without Public Accountability: Disclosures”

(4) Summary of material accounting policies:

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as “the Regulations”) and IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by the Financial Supervisory Commission (hereinafter referred to as FSC). The consolidated financial statements do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (altogether referred to “IFRS Accounting Standards” endorsed by the FSC) for a complete set of the annual consolidated financial statements.

Except the following accounting policies mentioned below, the material accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2024. For the related information, please refer to note 4 of the consolidated financial statements for the year ended December 31, 2024.

(b) Basis of consolidation

(i) List of subsidiaries in the consolidated financial statements:

Name of investor	Name of subsidiary	Principal activity	Shareholding			Note
			September 30, 2025	December 31, 2024	September 30, 2024	
The Company	BIOTEQUE MEDICAL PHIL. INC.	Manufacturing and Trading of Medical equipment	100.00 %	100.00 %	100.00 %	
BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	Trading of Medical equipment	100.00 %	100.00 %	100.00 %	

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(c) Income taxes

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of IAS 34 “Interim Financial Reporting”.

Income tax expenses for the period are measured by multiplying together the pre-tax income for the interim reporting period and the management’s best estimate of effective annual tax rate. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(d) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IAS 34 “Interim Financial Reporting” endorsed by the FSC requires management to make judgments, and estimates about the future, including climate-related risks and opportunities, that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The preparation of the consolidated interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2024.

(6) Explanation of significant accounts:

Except for the following disclosures, there is no significant difference as compared with those disclosed in the consolidated financial statements for the year ended December 31, 2024. Please refer to Note 6 of the 2024 annual consolidated financial statements.

(a) Cash and cash equivalents

	September 30, 2025	December 31, 2024	September 30, 2024
Cash on hand	\$ 711	670	972
Cash in bank	<u>999,765</u>	<u>1,236,285</u>	<u>1,318,130</u>
Cash and cash equivalents in the consolidated statement of cash flows	<u>\$ 1,000,476</u>	<u>1,236,955</u>	<u>1,319,102</u>

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(b) Current financial assets at fair value through profit or loss

	September 30, 2025	December 31, 2024	September 30, 2024
Mandatorily measured at fair value through profit or loss:			
Non-derivative financial assets			
Money market funds and bond funds	\$ <u>121,632</u>	<u>120,280</u>	<u>119,834</u>
(i) For credit risk and market risk, please refer to note 6(q).			
(ii) The financial assets of the Group were not collateralized.			
(c) Current financial assets measured at amortized cost			
Time deposits	<u>\$ 394,691</u>	<u>239,213</u>	<u>5,647</u>

The Group has assessed that these financial assets are held-to-maturity to collect contractual cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments were classified as financial assets measured at amortized cost.

(i) For the nine months ended September 30, 2025 and 2024, the Group held time deposits, with weighted-average interest rates of 1.53%~4.25% and 1.29%~4.575%, respectively, which mature between October of 2025 and January of 2026, and in December of 2024, respectively.

(ii) For credit risk, please refer to note 6(q).

(iii) The financial assets of the Group were not collateralized.

(d) Notes and accounts receivables

	September 30, 2025	December 31, 2024	September 30, 2024
Notes receivable	\$ 86,978	75,470	85,265
Accounts receivables	<u>194,211</u>	<u>192,657</u>	<u>192,593</u>
	<u>\$ 281,189</u>	<u>268,127</u>	<u>277,858</u>

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The Group applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, receivables have been grouped based on shared credit risk characteristics and the days past due, as well as incorporated forward looking information. The loss allowances were determined as follows:

	September 30, 2025		
	Gross carrying amount	Weighted-average loss rate	Loss allowance
Current	\$ 280,458	-	-
1 to 30 days past due	731	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	-	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	-	-
151 to 180 days past due	-	-	-
More than 181 days past due	<hr style="border-top: 1px solid black; border-bottom: none; border-left: none; border-right: none; margin-bottom: 2px; margin-top: 2px;"/>	100%	<hr style="border-top: 1px solid black; border-bottom: none; border-left: none; border-right: none; margin-bottom: 2px; margin-top: 2px;"/>
	\$ 281,189		-

	December 31, 2024		
	Gross carrying amount	Weighted-average loss rate	Loss allowance
Current	\$ 265,484	-	-
1 to 30 days past due	8	-	-
31 to 60 days past due	2,635	-	-
61 to 90 days past due	-	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	-	-
151 to 180 days past due	-	-	-
More than 181 days past due	<hr style="border-top: 1px solid black; border-bottom: none; border-left: none; border-right: none; margin-bottom: 2px; margin-top: 2px;"/>	100%	<hr style="border-top: 1px solid black; border-bottom: 3px double black; margin-bottom: 2px; margin-top: 2px;"/>
	\$ 268,127		-

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	September 30, 2024		
	Gross carrying amount	Weighted-average loss rate	Loss allowance
Current	\$ 271,815	-	-
1 to 30 days past due	6,043	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	-	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	-	-
151 to 180 days past due	-	-	-
More than 181 days past due	-	100%	-
	\$ 277,858		

The allowance for impairment remained unchanged for the nine months ended September 30, 2024 and September 30, 2025, and the balance of the allowance for impairment as of September 30, 2025 and September 30, 2024 were both \$0.

The notes and accounts receivables of the Group were not collateralized.

For further credit risk information, please refer to note 6(q).

(e) Inventories

	September 30, 2025	December 31, 2024	September 30, 2024
Raw materials	\$ 134,335	166,523	152,426
Work in progress	67,658	66,133	53,044
Finished goods	49,356	56,369	58,155
Merchandise	14,412	11,621	10,971
Inventories in transit	33,840	20,055	12,727
	\$ 299,601	320,701	287,323

Except for cost of goods sold and inventories recognized as operating cost, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Gains on physical inventory	\$ (266)	(431)	(819)	(1,031)
Unallocated production overheads	21,643	23,694	65,247	65,402
Losses on valuation of inventories	993	700	5,098	2,500
	\$ 22,370	23,963	69,526	66,871

The inventories of the Group were not collateralized.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(f) Property, plant and equipment

The cost and accumulated depreciation of the property, plant and equipment of the Group for the nine months ended September 30, 2025 and 2024 were as follows:

	<u>Land</u>	<u>Building and structures</u>	<u>Machinery and equipment</u>	<u>Transportation equipment</u>	<u>Office equipment</u>	<u>Other equipment</u>	<u>Construction in progress</u>	<u>Total</u>
Cost:								
Balance at January 1, 2025	\$ 91,834	2,041,818	1,025,860	13,997	39,721	263,867	-	3,477,097
Additions	-	-	8,113	-	1,190	14,428	1,437	25,168
Disposals	-	-	(6,231)	-	-	(607)	-	(6,838)
Reclassification (Note 1)	-	-	21,486	-	2,839	8,799	(1,437)	31,687
Effect on changes in foreign exchange rates	-	(28,119)	(11,797)	(202)	(196)	(6,191)	-	(46,505)
Balance at September 30, 2025	<u>\$ 91,834</u>	<u>2,013,699</u>	<u>1,037,431</u>	<u>13,795</u>	<u>43,554</u>	<u>280,296</u>	<u>-</u>	<u>3,480,609</u>
Balance at January 1, 2024	\$ 91,834	1,819,008	994,554	11,385	22,295	241,428	57,981	3,238,485
Additions	-	65,991	8,832	2,476	6,815	5,314	2,219	91,647
Disposals	-	(5,943)	-	-	-	(1,354)	-	(7,297)
Reclassification (Note 1)	-	132,019	3,326	-	12,121	8,644	(58,417)	97,693
Effect on changes in foreign exchange rates	-	11,331	4,687	38	6	2,415	(22)	18,455
Balance at September 30, 2024	<u>\$ 91,834</u>	<u>2,022,406</u>	<u>1,011,399</u>	<u>13,899</u>	<u>41,237</u>	<u>256,447</u>	<u>1,761</u>	<u>3,438,983</u>
Accumulated depreciation and impairment loss:								
Balance at January 1, 2025	\$ -	376,048	799,947	10,177	21,947	238,452	-	1,446,571
Depreciation	-	41,290	51,076	816	4,103	15,533	-	112,818
Disposals	-	-	(6,231)	-	-	(607)	-	(6,838)
Effect on changes in foreign exchange rates	-	(5,251)	(8,259)	(142)	(154)	(5,705)	-	(19,511)
Balance at September 30, 2025	<u>\$ -</u>	<u>412,087</u>	<u>836,533</u>	<u>10,851</u>	<u>25,896</u>	<u>247,673</u>	<u>-</u>	<u>1,533,040</u>
Balance at January 1, 2024	\$ -	321,739	726,148	8,925	20,934	213,859	-	1,291,605
Depreciation	-	37,301	50,882	813	2,249	16,134	-	107,379
Disposals	-	-	-	-	-	(1,354)	-	(1,354)
Effect on changes in foreign exchange rates	-	1,758	2,613	49	3	1,994	-	6,417
Balance at September 30, 2024	<u>\$ -</u>	<u>360,798</u>	<u>779,643</u>	<u>9,787</u>	<u>23,186</u>	<u>230,633</u>	<u>-</u>	<u>1,404,047</u>
Carrying amounts:								
Balance at January 1, 2025	<u>\$ 91,834</u>	<u>1,665,770</u>	<u>225,913</u>	<u>3,820</u>	<u>17,774</u>	<u>25,415</u>	<u>-</u>	<u>2,030,526</u>
Balance at September 30, 2025	<u>\$ 91,834</u>	<u>1,601,612</u>	<u>200,898</u>	<u>2,944</u>	<u>17,658</u>	<u>32,623</u>	<u>-</u>	<u>1,947,569</u>
Balance at January 1, 2024	<u>\$ 91,834</u>	<u>1,497,269</u>	<u>268,406</u>	<u>2,460</u>	<u>1,361</u>	<u>27,569</u>	<u>57,981</u>	<u>1,946,880</u>
Balance at September 30, 2024	<u>\$ 91,834</u>	<u>1,661,608</u>	<u>231,756</u>	<u>4,112</u>	<u>18,051</u>	<u>25,814</u>	<u>1,761</u>	<u>2,034,936</u>

(Note 1) Prepayments for business facilities were reclassified as property, plant and equipment.

The property, plant and equipment of Group were not collateralized.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(g) Right-of-use assets

The Group leases land and buildings. Information about leases for which the Group has been a lessee is presented below:

	Land	Buildings and structures	Total
Cost:			
Balance at January 1, 2025	\$ 380,494	31,837	412,331
Additions	296	21,013	21,309
Disposals	(294)	(1,605)	(1,899)
Effect on changes in foreign exchange rates	(4,443)	(445)	(4,888)
Balance at September 30, 2025	<u><u>\$ 376,053</u></u>	<u><u>50,800</u></u>	<u><u>426,853</u></u>
Balance at January 1, 2024	\$ 370,150	31,794	401,944
Additions	6,636	-	6,636
Disposals	(290)	-	(290)
Effect on changes in foreign exchange rates	1,552	37	1,589
Balance at September 30, 2024	<u><u>\$ 378,048</u></u>	<u><u>31,831</u></u>	<u><u>409,879</u></u>
Accumulated depreciation:			
Balance at January 1, 2025	\$ 41,402	30,462	71,864
Depreciation	6,979	5,042	12,021
Disposals	(294)	(1,605)	(1,899)
Effect on changes in foreign exchange rates	(925)	(100)	(1,025)
Balance at September 30, 2025	<u><u>\$ 47,162</u></u>	<u><u>33,799</u></u>	<u><u>80,961</u></u>
Balance at January 1, 2024	\$ 31,521	25,242	56,763
Depreciation	6,996	3,904	10,900
Disposals	(290)	-	(290)
Effect on changes in foreign exchange rates	104	36	140
Balance at September 30, 2024	<u><u>\$ 38,331</u></u>	<u><u>29,182</u></u>	<u><u>67,513</u></u>
Carrying amount:			
Balance at January 1, 2025	\$ 339,092	1,375	340,467
Balance at September 30, 2025	<u><u>\$ 328,891</u></u>	<u><u>17,001</u></u>	<u><u>345,892</u></u>
Balance at January 1, 2024	<u><u>\$ 338,629</u></u>	<u><u>6,552</u></u>	<u><u>345,181</u></u>
Balance at September 30, 2024	<u><u>\$ 339,717</u></u>	<u><u>2,649</u></u>	<u><u>342,366</u></u>

(h) Short-term and long-term borrowings

(i) Short-term borrowings

	September 30, 2025	December 31, 2024	September 30, 2024
Unsecured bank loans	\$ -	-	-
Unused credit lines	<u><u>\$ 762,037</u></u>	<u><u>769,057</u></u>	<u><u>795,667</u></u>
Range of interest rate	-	-	-

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Long-term borrowings

	September 30, 2025	December 31, 2024	September 30, 2024
Unsecured bank loans	\$ 333,879	446,229	483,679
Less: Current portion	147,025	149,800	149,800
Unsecured long-term borrowings	<u>\$ 186,854</u>	<u>296,429</u>	<u>333,879</u>
Unused credit lines	<u>\$ 150,000</u>	<u>150,000</u>	-
Range of interest rate	<u>1.38%~1.45%</u>	<u>1.38%~1.48%</u>	<u>1.375%~1.475%</u>

As of September 30, 2025, the details of the future repayment periods and amounts of the Group's long-term borrowings were as follows:

Period	Amount
2025.10.01~2026.09.30	\$ 147,025
2026.10.01~2027.09.30	134,250
2027.10.01~2028.09.30	52,604
	<u>\$ 333,879</u>

(iii) The Group has not pledged any assets as collateral for borrowing and credited lines.

(i) Lease liabilities

	September 30, 2025	December 31, 2024	September 30, 2024
Current	<u>\$ 14,751</u>	<u>8,952</u>	<u>10,240</u>
Non-current	<u>\$ 289,711</u>	<u>285,452</u>	<u>287,343</u>

For the maturity analysis, please refer to note 6(q).

The amounts recognized in profit or loss were as follows:

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Interest on lease liabilities	<u>\$ 639</u>	<u>453</u>	<u>1,663</u>	<u>1,376</u>
Expenses relating to leases of low-value assets	<u>\$ 15</u>	<u>14</u>	<u>52</u>	<u>44</u>

The amounts recognized in the statement of cash flows by the Group were as follows:

	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Total cash outflow for leases	<u>\$ 12,320</u>	<u>11,013</u>

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

For the nine months ended September 30, 2025 and September 30, 2024, the Group leases land, buildings and structures for its office space, warehouse and parking lot. The leases run for a period of 2 to 20 years. Some leases include an option to renew the lease for an additional period of 2 to 20 years after the end of the contract term.

Some leases of equipment contain extension options exercisable. These leases are negotiated and monitored by local management, and accordingly, contain a wide range of different terms and conditions. The extension options held are exercisable only by the Group and not by the lessors. In which leasee is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

(j) Employee benefits

(i) Defined benefit plans

Management believes that there was no material volatility of the market, no material reimbursement and settlement or other material one time events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2024 and 2023.

The expenses recognized in profit or loss for the Group were as follows:

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Operating costs	\$ 76	77	228	230
Operating expenses	337	192	732	577
	<u>\$ 413</u>	<u>269</u>	<u>960</u>	<u>807</u>

(ii) Defined contribution plans

The pension costs incurred from the contributions to the Bureau of the Labor Insurance were as follow:

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Operating costs	\$ 1,434	1,542	4,358	4,434
Operating expenses	798	764	2,398	2,308
	<u>\$ 2,232</u>	<u>2,306</u>	<u>6,756</u>	<u>6,742</u>

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iii) The Group's subsidiaries incorporated in the Philippine have a defined contribution plan, wherein a monthly contribution to an independent fund, administered by the government in accordance with the pension regulations in the Republic of the Philippines, are based on certain percentage of employees' monthly salaries and wages. The Group recognized the pension costs were as follows:

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Operating costs	\$ 62	53	177	132
Operating expenses	28	23	85	68
	\$ 90	76	262	200

(k) Income taxes

The amounts of income tax were as follows:

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Current tax expenses	\$ 40,103	40,860	97,811	108,412
Adjustment for prior periods	-	-	250	(800)
Income tax expenses (benefit)	\$ 40,103	40,860	98,061	107,612

The Company's income tax returns for all years through 2023 were assessed by the tax authorities.

(l) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the periods from January 1 to September 30, 2025 and 2024. For the related information, please refer to note 6(l) of the consolidated financial statements for the year ended December 31, 2024.

(i) Capital surplus

Balances of capital surplus at the reporting date were as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Share capital	\$ 315,168	315,168	315,168
Donation from shareholders	1,861	1,864	1,760
	\$ 317,029	317,032	316,928

According to the R.O.C. Company Act, capital surplus can only be used to offset a deficit, and only the realized capital surplus can be used to increase the common stock or be distributed as cash dividends. The aforementioned realized capital surplus includes capital surplus resulting from premium on issuance of capital stock and earnings from donated assets received. According to the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, capital increases by transferring capital surplus in excess of par value should not exceed 10% of the total common stock outstanding.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Retained earnings

The Company's Articles of Incorporation stipulate that 10% of the annual income or earnings, after deducting any accumulated deficit, shall be set aside as a legal reserve. When the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. If there are surplus profits remaining, at least 20% shall be allocated for distribution of shareholder dividends. The Board of Directors drafts a dividend distribution proposal and submits it to the shareholders meeting for resolution, in which cash dividends should make up at least 20% or more.

The Company should distribute dividends, bonuses, and capital reserves with cash. Distribution of dividends shall be undertaken by a resolution adopted by a majority vote at a Board meeting attended by at least two-thirds of the total number of directors, and a report of such distribution shall be submitted to the shareholders' meeting.

Because the industry the Company is involved in is undergoing a steady period of growth, the conditions, amount, and type of dividends mentioned in the preceding articles can be adjusted in response to the shifting market conditions and industry changes. In the mean time, the Company should consider the sustainable development and capital needs.

1) Legal reserve

When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

2) Special reserve

In accordance with Ruling No. 1010012865 issued by the FSC on April 6, 2012, a portion of current-period earnings and undistributed prior-period earnings shall be reclassified as special earnings reserve during earnings distribution. The amount to be reclassified should equal the current-period total net reduction of other shareholders' equity. Similarly, a portion of undistributed prior-period earnings shall be reclassified as special earnings reserve (which does not qualify for earnings distribution) to account for cumulative changes to other shareholders' equity pertaining to prior periods. The amounts of subsequent reversals pertaining to the net reduction of other shareholders' equity shall qualify for additional distributions.

3) Earnings distribution

On March 6, 2025 and March 6, 2024, the board of directors' meeting resolved to distribute the 2024 and 2023 earnings. These earnings were appropriated as follows:

	2024		2023	
	Amount per share (NTD)	Amount	Amount per share (NTD)	Amount
Dividends distributed to ordinary shareholders:				
Cash	\$ 5.00	\$ <u>346,492</u>	4.50	<u>311,843</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iii) Other equity

	Exchange differences on translation of foreign financial statements
Balance at January 1, 2025	\$ 44,718
Exchange differences on foreign operations	<u>(42,731)</u>
Balance at September 30, 2025	<u><u>\$ 1,987</u></u>
	Exchange differences on translation of foreign financial statements
Balance at January 1, 2024	\$ 10,683
Exchange differences on foreign operations	<u>16,102</u>
Balance at September 30, 2024	<u><u>\$ 26,785</u></u>

(m) Earnings per share

The Company's earnings per share were calculated as follows:

(i) Basic earnings per share

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Profit attributable to ordinary shareholders of the Company	\$ 136,632	143,825	383,633	394,033
Weighted-average number of ordinary shares (in thousand shares)	<u>69,298</u>	<u>69,298</u>	<u>69,298</u>	<u>69,298</u>
Basic earnings per share (express in New Taiwan Dollars)	<u><u>\$ 1.97</u></u>	<u><u>2.08</u></u>	<u><u>5.54</u></u>	<u><u>5.69</u></u>

(ii) Diluted earnings per share

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Profit attributable to ordinary shareholders of the Company	\$ 136,632	143,825	383,633	394,033
Weighted-average number of ordinary shares (basic) (in thousand shares)	69,298	69,298	69,298	69,298
Effect on employee remuneration (in thousand shares)	227	203	291	264
Weighted-average number of ordinary shares (diluted) (in thousand shares)	<u>69,525</u>	<u>69,501</u>	<u>69,589</u>	<u>69,562</u>
Diluted earnings per share (express in New Taiwan Dollars)	<u><u>\$ 1.97</u></u>	<u><u>2.07</u></u>	<u><u>5.51</u></u>	<u><u>5.66</u></u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(n) Revenue from contracts with customers

(i) Disaggregation of revenue

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Primary geographical markets:				
Asia	\$ 252,429	271,131	745,463	722,054
South Americas	50,921	46,989	112,230	134,487
North Americas	75,365	72,776	255,877	230,518
Others	140,548	162,417	454,713	481,269
Total	\$ 519,263	553,313	1,568,283	1,568,328
Major products service lines:				
Manufacturing, trading and selling of medical consumables	\$ 519,263	553,313	1,568,283	1,568,328

(ii) Contract balances

	September 30, 2025	December 31, 2024	September 30, 2024
Notes and accounts receivable	\$ 281,189	268,127	277,858
Less: allowance for impairment	-	-	-
Total	\$ 281,189	268,127	277,858
	September 30, 2025	December 31, 2024	September 30, 2024
Current contract liabilities	\$ 63,316	57,542	42,091

For details on notes and accounts receivable and allowance for impairment, please refer to note 6(d).

The amount of revenue recognized for the nine months ended September 30, 2025 and September 30, 2024 that was included in the contract liability balance at the beginning of the period were \$56,305 thousand and \$32,612 thousand, respectively.

The major change in the balance of contract assets and liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(o) Remuneration to employees and directors

On June 19, 2025, the Company resolved at the shareholders' meeting to amend its Articles of Incorporation. According to the amended Articles, if the Company has profit in a given fiscal year, more than 5% of the profits shall be allocated as employees' remuneration and salaries adjustment to those base-level employees and no more than 1.6% of the profits shall be allocated as directors' remuneration. Prior to the amendments, the Article of Incorporation stipulated that, if the Company has profit in a given fiscal year, no less than 5% shall be allocated as employee's remuneration and no more than 1.6% shall be allocated as directors' remuneration. However, if there are any accumulated losses of the Company, the Company shall pre-reserve the amount to offset the loss.

The Company's estimated remuneration is as follows:

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Employees' remuneration	\$ 11,003	9,755	27,101	26,448
Directors' remuneration	2,956	3,121	8,107	8,463
	\$ 13,959	12,876	35,208	34,911

The amount of employees' remuneration, and directors' remuneration were estimated based on profit before tax, net of the amount of the remuneration, and multiplied by the rule of Company's Article of Association. The above remuneration were included in the operating expenses of the nine months ended September 30, 2025 and September 30, 2024. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

The remunerations to employees amounted to \$35,687 thousand and \$30,179 thousand, respectively, for the years ended the us and December 31, 2024 and 2023. The remunerations to directors amounted to \$11,420 thousand and \$9,657 thousand, respectively, for the years ended December 31, 2024 and 2023.

There was no difference between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statement for the years of 2024 and 2023.

The related information mentioned above can be found on websites such as the Market Observation Post System.

(p) Non-operating income and expenses

(i) Interest income

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Interest income:				
Interest income from deposit	\$ 5	4	15	14
Interest income from bank deposit	3,375	2,850	11,735	9,592
Others	-	53	-	252
	\$ 3,380	2,907	11,750	9,858

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Other income

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Subsidy revenue	\$ 78	77	834	144
Compensation income	-	4,917	9	5,042
Rent revenue	197	196	406	696
Others	<u>607</u>	<u>1,160</u>	<u>2,604</u>	<u>2,898</u>
	<u>\$ 882</u>	<u>6,350</u>	<u>3,853</u>	<u>8,780</u>

(iii) Other gains and losses

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Foreign exchange gains (losses)	\$ 6,287	(3,507)	(15,577)	11,372
Gains on financial assets at fair value through profit or loss	446	440	1,352	1,243
Gains (losses) on financial assets at amortized cost	(680)	(1,401)	(3,585)	3,748
Others	<u>(75)</u>	<u>(5,977)</u>	<u>(236)</u>	<u>(6,273)</u>
	<u>\$ 5,978</u>	<u>(10,445)</u>	<u>(18,046)</u>	<u>10,090</u>

(iv) Finance costs

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Interest expense on bank borrowings	\$ 1,283	1,773	4,144	5,864
Interest expense on lease liabilities	639	453	1,663	1,376
	<u>\$ 1,922</u>	<u>2,226</u>	<u>5,807</u>	<u>7,240</u>

(q) Financial instruments

Except for the content mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information please refer to note 6(q) of the consolidated financial statements for the year ended December 31, 2024. Regarding how the financial instruments are considered to have low credit risk, please refer to note 4(g) of the consolidated financial statements for the year ended December 31, 2024.

(i) Credit risk

1) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

As of September 30, 2025, December 31, 2024 and September 30, 2024, 41%, 23% and 39% of the Group's notes and accounts receivable were concentrated on three, one and three specific customers respectively. Accordingly, concentrations of credit risk exist.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

2) Receivables securities

For credit risk exposure of notes and trade receivables, please refer to note 6(d).

Other financial assets at amortized cost are mainly time deposits. These financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses. For the correlated credit risk, please refer to note 6(d).

(ii) Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments and excluding the impact of netting agreements.

	Carrying amount	Contractual cash flows	1 year	1-2 years	2-5 years	Over 5 years
September 30, 2025						
Non-derivative financial liabilities						
Notes payable	\$ 235	235	235	-	-	-
Accounts payable	101,533	101,533	101,533	-	-	-
Other payables	138,142	138,142	138,142	-	-	-
Payables on machinery and equipment	8,166	8,166	8,166	-	-	-
Long-term borrowings (including current portion)	333,879	336,552	148,756	135,105	52,691	-
Lease liabilities (current and non-current)	<u>304,462</u>	<u>336,664</u>	<u>17,125</u>	<u>16,646</u>	<u>31,360</u>	<u>271,533</u>
	\$ 886,417	921,292	413,957	151,751	84,051	271,533
December 31, 2024						
Non-derivative financial liabilities						
Notes payable	\$ 289	289	289	-	-	-
Accounts payable	114,547	114,547	114,547	-	-	-
Other payables	140,334	140,334	140,334	-	-	-
Payables on machinery and equipment	7,995	7,995	7,995	-	-	-
Long-term borrowings (including current portion)	446,229	450,729	152,103	144,692	153,934	-
Lease liabilities (current and non-current)	<u>294,404</u>	<u>326,320</u>	<u>10,692</u>	<u>9,283</u>	<u>27,849</u>	<u>278,496</u>
	\$ 1,003,798	1,040,214	425,960	153,975	181,783	278,496
September 30, 2024						
Non-derivative financial liabilities						
Notes payable	\$ 190	190	190	-	-	-
Accounts payable	112,769	112,769	112,769	-	-	-
Other payables	132,417	132,417	132,417	-	-	-
Payables on machinery and equipment	24,470	24,470	24,470	-	-	-
Long-term borrowings (including current portion)	483,679	488,916	152,361	148,759	187,796	-
Lease liabilities (current and non-current)	<u>297,583</u>	<u>329,945</u>	<u>11,996</u>	<u>9,283</u>	<u>27,850</u>	<u>280,816</u>
	\$ 1,051,108	1,088,707	434,203	158,042	215,646	280,816

The Group does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amount.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iii) Market risk

1) Currency risk

The Group's significant exposure to foreign currency risk was as follows:

	September 30, 2025			December 31, 2024			September 30, 2024		
	Foreign currency (in thousands)	Exchange rate	NTD	Foreign currency (in thousands)	Exchange rate	NTD	Foreign currency (in thousands)	Exchange rate	NTD
Financial assets									
Monetary items									
USD	\$ 7,637	30.44	232,472	11,288	32.78	370,032	12,368	31.65	391,440
EUR	554	35.80	19,847	781	34.15	26,670	255	35.43	9,043
JPY	32,279	0.21	6,654	31,051	0.21	6,528	69,259	0.22	15,393
PHP	194,560	0.53	102,338	193,523	0.57	109,714	173,584	0.57	98,596
CNY	13,459	4.27	57,524	16,501	4.48	73,858	12,638	4.53	57,226
Investments accounted for using equity method									
USD	16,266	30.44	495,141	15,561	32.78	510,102	15,363	31.65	486,253
PHP	168,941	0.53	88,863	131,558	0.57	74,584	117,007	0.57	66,460
Financial liabilities									
Monetary items									
USD	2,453	30.44	74,664	2,662	32.78	87,245	2,108	31.65	66,714
EUR	124	35.80	4,423	262	34.15	8,933	49	35.43	1,732
JPY	28,131	0.21	5,799	42,356	0.21	8,905	62,361	0.22	13,860
PHP	20,872	0.53	10,979	13,200	0.57	7,484	12,255	0.57	6,961

The Group's exposure to foreign currency risk arise from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, accounts receivables, other receivables, accounts payable, other payables and payables on machinery and equipment that are denominated in foreign currency.

A depreciation (appreciation) of 1% of the NTD against the foreign currency for the nine months ended September 30, 2025 and September 30, 2024, would have increased (decreased), the net profit before tax by \$3,230 thousand and \$4,824 thousand, respectively. The analysis is performed on the same basis for 2024.

Since the Group has many kinds of functional currencies, the information on foreign exchange gain (loss) on monetary items is disclosed by total amount. For the nine months ended September 30, 2025 and September 30, 2024, foreign exchange gains or losses (including realized and unrealized portions) amounted to \$(15,577) thousand and \$11,372 thousand, respectively.

2) Interest rate analysis

Please refer to the notes on liquidity risk management and interest rate exposure of the Group's financial assets and liabilities.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The following sensitivity analysis is based on the exposure to the interest rate risk of non-derivative financial instruments on the reporting date. Regarding assets with variable interest rates, the analysis is based on the assumption that the amount of assets outstanding at the reporting date was outstanding throughout the year. The rate of change is expressed as the interest rate increases or decreases by 1% when reporting to management internally, which also represents the Group management's assessment of the reasonably possible interest rate change.

If the interest rate had increased / decreased by 1% basic points, the Group's net profit before tax would have decreased / increased by \$2,504 thousand and \$3,628 thousand and for the nine months ended September 30, 2025 and September 30, 2024, respectively, with all other variable factors remain constant. This is mainly due to the Group's borrowing at floating rates.

3) Other market price risk

For the nine months ended September 30, 2025 and September 30, 2024, the sensitivity analyzes for the changes in the securities price at the reporting date were performed using the same basis for the profit and loss as illustrated below:

Prices of securities at the reporting date	For the nine months ended September 30			
	2025		2024	
	Other comprehensive income before tax	Net profit before tax	Other comprehensive income before tax	Net profit before tax
Increasing 1%	\$ -	1,216	-	1,198
Decreasing 1%	\$ -	(1,216)	-	(1,198)

(iv) Fair value of financial instruments

1) Fair value hierarchy

The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows, however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

	September 30, 2025				
	Book value	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 121,632	121,632	-	-	121,632
Financial assets measured at amortized cost					
Cash and cash equivalents	1,000,476	-	-	-	-
Financial assets measured at amortized cost	394,691	-	-	-	-
Receivables	281,189	-	-	-	-
Other financial assets	4,680	-	-	-	-
Subtotal	1,681,036	-	-	-	-
Total	\$ 1,802,668	121,632	-	-	121,632

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

September 30, 2025				
	Fair value			
Book value	Level 1	Level 2	Level 3	Total
Financial liabilities measured at amortized cost				
Notes and accounts payable	\$ 101,768	-	-	-
Other payables	138,142	-	-	-
Payables on machinery and equipment	8,166	-	-	-
Long-term borrowings (including current portion)	333,879	-	-	-
Lease liabilities (current and non-current)	304,462	-	-	-
Total	\$ 886,417	-	-	-
December 31, 2024				
	Fair value			
Book value	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss				
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 120,280	120,280	-	120,280
Financial assets measured at amortized cost				
Cash and cash equivalents	1,236,955	-	-	-
Financial assets measured at amortized cost	239,213	-	-	-
Receivables	268,127	-	-	-
Other financial assets	4,256	-	-	-
Subtotal	1,748,551	-	-	-
Total	\$ 1,868,831	120,280	-	120,280
Financial liabilities measured at amortized cost				
Notes and accounts payable	\$ 114,836	-	-	-
Other payables	140,334	-	-	-
Payables on machinery and equipment	7,995	-	-	-
Long-term borrowings (including current portion)	446,229	-	-	-
Lease liabilities (current and non-current)	294,404	-	-	-
Total	\$ 1,003,798	-	-	-
September 30, 2024				
	Fair value			
Book value	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss				
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 119,834	119,834	-	119,834
Financial assets measured at amortized cost				
Cash and cash equivalents	1,319,102	-	-	-
Financial assets measured at amortized cost	5,647	-	-	-
Receivables	277,858	-	-	-
Other financial assets	4,230	-	-	-
Subtotal	1,606,837	-	-	-
Total	\$ 1,726,671	119,834	-	119,834
Financial liabilities measured at amortized cost				
Notes and accounts payable	\$ 112,959	-	-	-
Other payables	132,417	-	-	-
Payables on machinery and equipment	24,470	-	-	-
Long-term borrowings (including current portion)	483,679	-	-	-
Lease liabilities (current and non-current)	297,583	-	-	-
Total	\$ 1,051,108	-	-	-

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

2) Valuation techniques for financial instruments measured at fair value

A financial instrument is regarded as being quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm's-length basis. Whether transactions are taking place 'regularly' is a matter of judgment and depends on the facts and circumstances of the market for the instrument.

Quoted market prices may not be indicative of the fair value of an instrument if the activity in the market is infrequent, the market is not well-established, only small volumes are traded, or bid-ask spreads are very wide. Determining whether a market is active involves judgment.

When the financial instruments of the Group are traded in an active market, its fair value is illustrated by the category and nature as follows:

The fair value of listed stocks and funds traded in an active market is based on the market quoted price.

Measurements of fair value of financial instruments without an active market are based on valuation technique or quoted price from a competitor. Fair value, measured by using valuation technique that can be extrapolated from either similar financial instruments or discounted cash flow method or other valuation techniques, including models, is calculated based on available market date at the reporting date.

3) Categories and fair values of financial instruments

The Group strives to use market observable inputs when measuring assets and liabilities. Different levels of the fair value hierarchy to be used in determining the fair value of financial instruments are as follows:

- a) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- b) Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c) Level 3: inputs for the assets or liability that are not based on observable market data (unobservable inputs).

For the nine months ended September 30, 2025 and September 30, 2024, there were no changes on the fair value hierarchy of financial asset.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(r) Financial risk management

There were no significant changes in the Group's financial risk management and policies as disclosed in note 6(r) of the consolidated financial statements for the year ended December 31, 2024.

(s) Capital management

Management believes that the objectives, policies and processes of capital management of the Group have been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2024. Also, management believes that there were no significant changes in the Group's capital management information as disclosed for the year ended December 31, 2024. Please refer to Note 6(s) of the consolidated financial statements for the year ended December 31, 2024 for further details.

(t) Investing and financing activities not affecting current cash flow

The Group's financial activities which did not affect the current cash flow for the nine months ended September 30, 2025 and September 30, 2024 were as follows:

(i) For right-of-use assets under leases, please refer to note 6(g).

(ii) Reconciliation of liabilities arising from financial activities was as follows:

	January 1, 2025	Cash flows	Non-cash changes		September 30, 2025
			Foreign exchange movement	Other	
Long-term borrowings (including current portion)	\$ 446,229	(112,350)	-	-	333,879
Lease liabilities (current and non-current)	294,404	(10,605)	(350)	21,013	304,462
Total liabilities from financial activities	<u>\$ 740,633</u>	<u>(122,955)</u>	<u>(350)</u>	<u>21,013</u>	<u>638,341</u>

	January 1, 2024	Cash flows	Non-cash changes		September 30, 2024
			Foreign exchange movement	Other	
Long-term borrowings (including current portion)	\$ 593,693	(110,954)	940	-	483,679
Lease liabilities (current and non-current)	300,837	(9,593)	2	6,337	297,583
Total liabilities from financial activities	<u>\$ 894,530</u>	<u>(120,547)</u>	<u>942</u>	<u>6,337</u>	<u>781,262</u>

(7) Related-party transactions:

(a) Names and relationship with the Group

Name	Relationship with the Group
Keyao Co., Ltd.	The entity has significant influence over the Group
Yide Co., Ltd.	Other related party
Yisheng Co., Ltd.	Other related party

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(b) Significant transactions with related parties:

For the nine months ended September 30, 2025 and 2024, dividends paid to corporate shareholders were \$59,195 thousand and \$52,340 thousand, respectively.

(c) Key management personnel compensation

Key management personnel compensation was comprised as below:

	For the three months ended September 30, 2025	For the three months ended September 30, 2024	For the nine months ended September 30, 2025	For the nine months ended September 30, 2024
Short-term employee benefits	\$ 6,732	7,112	20,341	20,457
Post-employment benefits	318	174	675	522
	<u><u>\$ 7,050</u></u>	<u><u>7,286</u></u>	<u><u>21,016</u></u>	<u><u>20,979</u></u>

(8) Assets Pledged as security:

	Pledged assets	Pledged to secure	September 30, 2025	December 31, 2024	September 30, 2024
Other current financial assets:					
Restricted bank deposit		Purchase guarantee	\$ 601	601	601

(9) Commitments and contingencies:

(a) Contingencies

In prior years, the Group entered into the license agreement which has expired with a supplier. On July 5, 2018, the supplier filed a complaint which has not completed accusing the Group. The Group assess there is no significant impact on its financial statements.

(b) Notes issued as guarantee

	September 30, 2025	December 31, 2024	September 30, 2024
Bank borrowings and lease guarantee	<u><u>\$ 1,915,653</u></u>	<u><u>1,913,340</u></u>	<u><u>1,964,950</u></u>

(c) The agreements for expansion of the factory and purchases of machinery and equipment

	September 30, 2025	December 31, 2024	September 30, 2024
Total contract price	<u><u>\$ 94,541</u></u>	<u><u>33,707</u></u>	<u><u>32,004</u></u>
Paid amount	<u><u>\$ 21,937</u></u>	<u><u>24,855</u></u>	<u><u>23,141</u></u>

(10) Losses Due to Major Disasters: None

(11) Subsequent Events: None

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(12) Other:

A summary of employee benefits, depreciation, and amortization, by function, is as follows:

By function By item	For the three months ended September 30, 2025			For the three months ended September 30, 2024		
	Cost of sales	Operating expenses	Total	Cost of sales	Operating expenses	Total
Employee benefits						
Salary	60,323	32,581	92,904	54,179	28,405	82,584
Labor and health insurance	4,730	1,969	6,699	4,620	1,841	6,461
Pension	1,572	1,163	2,735	1,672	979	2,651
Remuneration of directors	-	2,956	2,956	-	3,121	3,121
Others	3,168	1,174	4,342	2,932	1,648	4,580
Depreciation	37,960	3,802	41,762	38,072	3,129	41,201
Amortization	597	460	1,057	363	497	860

By function By item	For the nine months ended September 30, 2025			For the nine months ended September 30, 2024		
	Cost of sales	Operating expenses	Total	Cost of sales	Operating expenses	Total
Employee benefits						
Salary	179,970	88,960	268,930	162,756	82,716	245,472
Labor and health insurance	14,441	6,040	20,481	13,210	5,744	18,954
Pension	4,763	3,215	7,978	4,796	2,953	7,749
Remuneration of directors	-	8,107	8,107	-	8,463	8,463
Others	9,228	3,652	12,880	8,825	4,221	13,046
Depreciation	114,043	10,796	124,839	109,631	8,648	118,279
Amortization	1,672	1,510	3,182	1,085	1,559	2,644

(d) Seasonality of operations

The Group's operations were not affected by seasonality or cyclical factors.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(13) Other disclosures:

(a) Information on significant transactions:

The followings is the information on the Group's significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the nine months ended September 30, 2025:

(i) Loans to other parties: None.

(ii) Guarantees and endorsements for other parties:

(In thousands of NTD and USD)

Number	Name of guarantor	Counterparty of guarantee and endorsement		Limitation on amount of guarantees and endorsements for a specific enterprise (Note 2)	Highest balance of guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	Ratio of accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 1)	Parent company endorsements/guarantees to third parties on behalf of subsidiary	Subsidiary endorsements/guarantees to third parties on behalf of parent company	Endorsements/guarantees to third parties on behalf of companies in Mainland China
		Name	Relationship with the Company (Note 3)										
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	2	207,894	99,540 (USD 3,000)	91,320 (USD 3,000)	-	-	2.66 %	339,561	Y	N	N

Note 1: The total amount for the guarantees and endorsements provided by the Company to external entities shall not exceed 49% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to external entities shall not exceed 49% of the Company's net worth.

Note 2: The total amount for the guarantees and endorsements provided by the Company to any individual entity shall not exceed 30% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to any individual entity shall not exceed 30% of the Company's net worth.

Note 3: Relationship with the Company

1. Ordinary business relationship.
2. An entity, directly and indirectly, owned more than 50% voting shares of a guarantor.
3. A guarantor, directly and indirectly, owned more than 50% voting shares of an entity.
4. An entity, directly and indirectly, owned more than 90% voting shares of a guarantor.
5. Fulfillment of contractual obligations by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.
6. An entity that is guaranteed and endorsed by all capital contributing shareholders in proportion to their shareholding percentages.
7. Peer engaged in the escrow of the sales contract on pre-sale house under the Consumer Protection Act.

(iii) Information regarding securities held at the reporting date (subsidiaries, associates and joint ventures not included):

(In thousands of NTD and shares)

Name of holder	Category and name of security	Relationship with company	Account title	Ending balance				Remark
				Shares/Units (in thousands)	Carrying value	Percentage of ownership (%)	Fair value	
The Company	Capital Money Market Fund	None	Current financial assets at fair value through profit or loss	641	10,901	- %	10,901	
"	Yuanta Wan Tai Money Market Fund	"	"	2,497	39,814	- %	39,814	
"	Franklin Templeton Sinoam Money Market Fund	"	"	2,992	32,640	- %	32,640	
"	Mega Diamond Money Market Fund	"	"	2,894	38,277	- %	38,277	
	Total				121,632			121,632

Note: If there are public markets prices, the fair value shall be evaluated by the last operating date of the accounting duration.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iv) Information regarding related-parties purchases and/or sales exceeding 100 million or 20% of the Company's paid-in capital: None.

(v) Information regarding receivables from related-parties exceeding 100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of company	Related party	Nature of relationship	Ending balance	Turnover rate	Overdue		Amounts received in subsequent period	Allowance for bad debts
					Amount	Action taken		
The Company	BIOTEQUE MEDICAL PHIL. INC.	Subsidiary	139,511	1.14 %	-	-	19,195	-

Note: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

(vi) Significant transactions and business relationship between the parent company and its subsidiaries for the nine months ended September 30, 2025:

(In thousands of New Taiwan Dollars)

No. (Note 1)	Name of company	Name of counter-party	Nature of relationship	Intercompany transactions			Percentage of the consolidated net revenue or total assets
				Account name	Amount	Trading terms	
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Accounts receivable	134,306	OA 270	2.99%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Processing costs	56,099	There is no significant difference from translation terms with non-related parties.	3.58%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Other receivables	5,205	OA 270	0.12%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Other payables	28	OA 60	-%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Accounts payable	49,500	OA 60	1.10%
0	The Company	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	1	Sales revenue	44,507	There is no significant difference from translation terms with non-related parties.	2.84%
0	The Company	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	1	Accounts receivable	14,146	OA 120	0.31%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Other receivables	173	OA 30	-%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Sales revenue	81,783	There is no significant difference from translation terms with non-related parties.	5.21%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Accounts receivable	13,171	OA 30	0.30%

Note 1: Company numbering as follows:

Parent company – 0

Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary – 1

Subsidiary to parent company – 2

Subsidiary to subsidiary – 3

Note 3: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(b) Information on investees:

The following are the information on investees for the nine months ended September 30, 2025 (excluding information on investees in Mainland China):

Name of investor	Name of investee	Location	Main businesses and products	Original investment amount		Balance as of September 30, 2025			Net income (losses) of investee	Share of profits (losses) of investee	Remark
				September 30, 2025	December 31, 2024	Shares (in thousands)	Percentage of ownership	Carrying value			
The Company	BIOTEQUE MEDICAL PHIL. INC.	Philippines	Manufacturing and Trading of Medical equipment	299,315	299,315	4,481	100 %	495,141	27,095	27,095	Subsidiary
BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	Philippines	Trading of Medical equipment	6,801	6,801	670	100 %	88,863	20,575	20,575	investment through subsidiary

Note 1: The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

(c) Information on investment in mainland China: None.

(14) Segment information:

There were no significant changes in the Group's segment, as well as the profit and loss measurement basis, as disclosed in the consolidated financial statements for the year ended December 31, 2024.

The Group's operating segment information and reconciliation were as follows:

	For the three months ended September 30, 2025					Total
	Segment A	Segment B	Segment C	Other Segment	Reconciliation and elimination	
Revenue:						
Revenue from external customers	\$ 158,837	96,980	244,526	18,920	-	519,263
Intersegment revenue	-	6,452	-	-	(6,452)	-
Total revenue	\$ 158,837	103,432	244,526	18,920	(6,452)	519,263
Reportable segment profit or loss	\$ 27,205	24,246	134,857	(9,573)	-	176,735
For the three months ended September 30, 2024						
	Segment A	Segment B	Segment C	Other Segment	Reconciliation and elimination	Total
Revenue:						
Revenue from external customers	\$ 157,005	106,207	276,334	13,767	-	553,313
Intersegment revenue	-	6,695	-	-	(6,695)	-
Total revenue	\$ 157,005	112,902	276,334	13,767	(6,695)	553,313
Reportable segment profit or loss	\$ 21,990	27,528	159,259	(24,092)	-	184,685
For the nine months ended September 30, 2025						
	Segment A	Segment B	Segment C	Other Segments	Reconciliation and elimination	Total
Revenue:						
Revenue from external customers	\$ 465,460	311,700	739,958	51,165	-	1,568,283
Intersegment revenue	-	19,714	-	-	(19,714)	-
Total revenue	\$ 465,460	331,414	739,958	51,165	(19,714)	1,568,283
Reportable segment profit or loss	\$ 71,318	77,459	401,863	(68,946)	-	481,694

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	For the nine months ended September 30, 2024					Total
	Segment A	Segment B	Segment C	Other Segments	Reconciliation and elimination	
Revenue:						
Revenue from external customers	\$ 497,987	282,846	764,288	23,207	-	1,568,328
Intersegment revenue	-	18,953	-	-	(18,953)	-
Total revenue	<u><u>\$ 497,987</u></u>	<u><u>301,799</u></u>	<u><u>764,288</u></u>	<u><u>23,207</u></u>	<u><u>(18,953)</u></u>	<u><u>1,568,328</u></u>
Reportable segment profit or loss	<u><u>\$ 58,046</u></u>	<u><u>62,766</u></u>	<u><u>420,714</u></u>	<u><u>(39,881)</u></u>	<u><u>-</u></u>	<u><u>501,645</u></u>

The material reconciling items of the above reportable segment are as below:

Total reportable segment revenue should eliminate intersegment revenue by \$6,452 thousand, \$6,695 thousand, \$19,714 thousand and \$18,953 thousand and for the three months and nine months ended September 30, 2025 and 2024, respectively.